Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Inclusion Criteria: * Histologically confirmed malignant solid tumor, including the following: * Osteosarcoma * Ewing sarcoma/peripheral primitive neuroectodermal tumor * Rhabdomyosarcoma * Neuroblastoma * Wilms tumor * Synovial sarcoma * Hepatoblastoma * Adrenocortical carcinoma * Retinoblastoma * No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists * Radiographically measurable disease\*, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by MRI or CT scan or ≥ 10 mm by spiral CT scan * The following are not considered measurable disease: * Ascites, pleural effusions, or other malignant fluid collections * Bone marrow infiltration by tumor * Lesions detected only by non-MIBG nuclear medicine studies (e.g., bone scan) * Previously irradiated lesions that have not demonstrated clear progression post-radiotherapy * No known Central Nervous System (CNS) metastases unless they were treated by surgery or radiotherapy AND are stable with no recurrent lesions for ≥ 3 months * Lansky or Karnofsky performance status (PS) 50-100% OR Eastern Cooperative Oncology Group (ECOG) PS 0-2 * Absolute neutrophil count (ANC) ≥ 1,000/mm³ (\> 250/mm³ for patients with neuroblastoma) * Platelet count ≥ 75,000/mm³ (\> 25,000/mm³ for patients with neuroblastoma) (transfusion independent) * Hemoglobin ≥ 8.0 g/dL (≥ 7.5 g/dL for patients with neuroblastoma) (RBC transfusion allowed) * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine normal based on age/gender as follows: * ≤ 0.4 mg/dL (for patients 1 to 5 months of age) * ≤ 0.5 mg/dL (for patients 6 to 11 months of age) * ≤ 0.6 mg/dL (for patients 1 year of age) * ≤ 0.8 mg/dL (for patients 2 to 5 years of age) * ≤ 1 mg/dL (for patients 6 to 9 years of age) * ≤ 1.2 mg/dL (for patients 10 to 12 years of age) * ≤ 1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age) * ≤ 1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients ≥ 16 years of age) * Total bilirubin ≤ 1.5 times upper limit of normal for age * Alanine transaminase (ALT) ≤ 110 U/L * Serum albumin ≥ 2 g/dL * Blood glucose normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * Able to comply with safety monitoring requirements of study * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug * No uncontrolled infection * No known type I or II diabetes mellitus * Recovered from prior chemotherapy, immunotherapy, or radiotherapy * More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) * At least 7 days since prior hematopoietic growth factors (14 days for pegfilgrastim) * At least 6 weeks since prior monoclonal antibody therapy * At least 7 days since other prior antineoplastic biologic agents * No prior monoclonal antibody targeting the IGF-IR * No prior small molecule kinase inhibitors of IGF-IR * At least 2 weeks since prior local palliative (small port) radiotherapy * At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis * At least 6 weeks since other prior substantial bone marrow radiotherapy * At least 2 months since prior stem cell transplantation * No evidence of graft-versus-host disease * Concurrent corticosteroids allowed provided dose is stable or decreasing over the past 7 days * Intermittent use of corticosteroids to manage infusional reactions allowed * No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy * No other concurrent investigational agents * No concurrent insulin or growth hormone therapy